EphA2 Gene Targeting using Neutral Liposomal Small Interfering RNA Delivery (IND# 72924): A Phase I Clinical Trial
MD Anderson Study Status
EphA2-targeting DOPC-encapsulated siRNA
This phase I trial studies the side effects and best dose of EphA2 siRNA (ephrin type-A receptor 2 [EphA2]-targeting 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine [DOPC]-encapsulated short-interfering ribonucleic acid [siRNA]) in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or have come back after a period of improvement (recurrent). EphA2-targeting DOPC-encapsulated siRNA may slow the growth of tumor cells by shutting down the activity of a gene that causes tumor growth.
Information and next steps
Advanced Malignant Solid Neoplasm
Gynecologic Oncology & Reproductive Medicine
For general questions about clinical trials: